Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Non-Current Assets: 2014-2025

Historic Non-Current Assets for Viking Therapeutics (VKTX) over the last 11 years, with Sep 2025 value amounting to $712,000.

  • Viking Therapeutics' Non-Current Assets fell 42.53% to $712,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $712,000, marking a year-over-year decrease of 42.53%. This contributed to the annual value of $1.1 million for FY2024, which is 12.65% down from last year.
  • As of Q3 2025, Viking Therapeutics' Non-Current Assets stood at $712,000, which was down 14.63% from $834,000 recorded in Q2 2025.
  • In the past 5 years, Viking Therapeutics' Non-Current Assets registered a high of $1.7 million during Q1 2022, and its lowest value of $134,000 during Q4 2021.
  • Over the past 3 years, Viking Therapeutics' median Non-Current Assets value was $1.2 million (recorded in 2024), while the average stood at $1.1 million.
  • As far as peak fluctuations go, Viking Therapeutics' Non-Current Assets crashed by 68.45% in 2021, and later skyrocketed by 1,011.19% in 2022.
  • Quarterly analysis of 5 years shows Viking Therapeutics' Non-Current Assets stood at $134,000 in 2021, then soared by 1,011.19% to $1.5 million in 2022, then fell by 15.04% to $1.3 million in 2023, then fell by 12.65% to $1.1 million in 2024, then plummeted by 42.53% to $712,000 in 2025.
  • Its Non-Current Assets stands at $712,000 for Q3 2025, versus $834,000 for Q2 2025 and $970,000 for Q1 2025.